iproniazid has been researched along with Alzheimer Disease in 31 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The multifactorial nature of Alzheimer's disease (AD) calls for the development of multitarget agents addressing key pathogenic processes." | 1.48 | Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties. ( Cai, P; Fang, SQ; Kong, LY; Liu, QH; Wang, XB; Yang, HL; Yang, XL, 2018) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (80.65) | 24.3611 |
| 2020's | 6 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, M | 1 |
| Xie, SS | 5 |
| Jiang, N | 4 |
| Lan, JS | 4 |
| Kong, LY | 6 |
| Wang, XB | 4 |
| Wang, X | 2 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Li, ZR | 1 |
| Wang, ZM | 1 |
| Li, F | 2 |
| Wu, JJ | 2 |
| Wang, J | 2 |
| Li, Y | 11 |
| Qiang, X | 9 |
| Luo, L | 8 |
| Xiao, G | 6 |
| Tan, Z | 13 |
| Deng, Y | 13 |
| Estrada, M | 1 |
| Herrera-Arozamena, C | 2 |
| Pérez, C | 2 |
| Viña, D | 2 |
| Romero, A | 2 |
| Morales-García, JA | 2 |
| Pérez-Castillo, A | 2 |
| Rodríguez-Franco, MI | 2 |
| Yang, X | 6 |
| Zheng, Y | 5 |
| Cao, Z | 10 |
| Sang, Z | 10 |
| Su, F | 2 |
| Liu, Q | 1 |
| Ai, J | 1 |
| Xu, R | 6 |
| Song, Q | 7 |
| Pan, W | 1 |
| Wang, K | 7 |
| Ma, Q | 3 |
| Yu, L | 3 |
| Liu, W | 6 |
| Yang, XL | 3 |
| Cai, P | 3 |
| Liu, QH | 3 |
| Ding, Y | 1 |
| Liu, Y | 1 |
| Kang, P | 1 |
| Hou, JW | 1 |
| Zhang, XY | 1 |
| Zhang, T | 1 |
| Wang, H | 4 |
| Ye, M | 2 |
| Han, X | 2 |
| Yang, J | 2 |
| Zhang, X | 2 |
| Liu, H | 2 |
| Yang, Z | 2 |
| Estrada Valencia, M | 1 |
| de Andrés, L | 1 |
| Ramos, E | 1 |
| Yáñez, M | 1 |
| Laurini, E | 1 |
| Pricl, S | 1 |
| Fang, SQ | 1 |
| Yang, HL | 2 |
| Tang, YW | 1 |
| Shi, CJ | 1 |
| Shi, J | 4 |
| Zhang, P | 3 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 2 |
| Bai, P | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Yu, G | 2 |
| Liu, Z | 2 |
| Liu, J | 1 |
| Tang, C | 1 |
| Pang, C | 1 |
| Li, Q | 1 |
| Qin, Y | 1 |
| Nong, X | 1 |
| Guo, J | 1 |
| Cheng, M | 1 |
| Tang, W | 1 |
| Liang, N | 1 |
| Cong, S | 1 |
| Zhang, L | 1 |
| Nam, G | 1 |
| Suh, JM | 1 |
| Yi, Y | 1 |
| Lim, MH | 1 |
31 other studies available for iproniazid and Alzheimer Disease
| Article | Year |
|---|---|
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tu | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
Topics: Alzheimer Disease; Amines; Animals; Antioxidants; Cell Line, Tumor; Cholinesterases; Drug Design; Hu | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inh | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Bra | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Donepezil; E | 2018 |
Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butylated Hyd | 2018 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Drug Discovery; Flurbiprofen; Humans; Ligands; | 2020 |
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Butyrylcholinestera | 2020 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose | 2020 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; | 2021 |
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Bindi | 2021 |
Drug repurposing: small molecules against Cu(II)-amyloid-β and free radicals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Copper; Drug Repositioning; Free Radicals; Humans; Hydrazi | 2021 |